Join Adagene for a virtual KOL event featuring Aurélien Marabelle, MD, PhD (University of Paris Saclay), Daneng Li, MD (City of Hope), and Marwan G. Fakih, MD (City of Hope), who will join company management to discuss the unmet need and current treatment landscape for patients with advanced/metastatic microsatellite-stable (MSS) colorectal cancer (CRC) and why CTLA-4 targeting is essential for achieving durable responses in this cold tumor type.

The event will provide a data update on the Phase 1b/2 study of ADG126 (muzastotug) in combination with KEYTRUDA^® (pembrolizumab) in advanced/metastatic MSS CRC being featured in a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place January 23-25 in San Francisco, California. ADG126 is an anti-CTLA-4 SAFEbody that targets a unique CTLA-4 epitope on regulatory T cells (Tregs) within the tumor microenvironment. It combines potent intratumoral Treg depletion via strong ADCC/ADCP with partial CTLA-4 blockade to softly prime effector T cells, delivering powerful anti-tumor activity with reduced toxicity.

A live question and answer session will follow the formal presentations.